NF-κB signature on the aging wall

Current Drug Metabolism

Volumn 11, Issue 3, 2010, Pages 266-275

  Zineldeen, Doaa Hussein ^a   Uranishi, Hiroaki ^b   Okamoto, Takashi ^b  

^a TANTA UNIVERSITY   (Egypt)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Activation cascades; Aging; mTOR; NF B; Sirtuins; SNARK

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR REL;

AGING; APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW;

ANIMALS; APOPTOSIS; CELL AGING; CELL DIFFERENTIATION; CELL MEMBRANE; HUMANS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 77951750888     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791196283     Document Type: Review

References (144)

1. Ghosh, S.; Karin, M. Missing pieces in the NF-kappa B puzzle. Cell, 2002, 109( Suppl), 81-96.
2. Singh, H.; Sen, R.; Baltimore, D.; Sharp, P.A. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature, 1986, 319(6049), 154-158.
3. Bonizzi,G.; Karin, M. The two NF-kappa B activation pathways and their role in innate and adaptive immunity. Trends Immunol., 2004, 25(6) 280-288. (Pubitemid 38610351)
4. Yang, J.P.; Hori, M.; Sanda, T.; Okamoto, T. Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J. Biol. Chem., 1999, 274(22), 15662-15670. (Pubitemid 129518922)
5. Zhong, H.; May, M.J.; Jimi, E.; Ghosh, S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol. Cell, 2002, 9(3), 625-636. (Pubitemid 34273792)
6. Dejardin, E.; Droin, N.M.; Delhase, M.; Haas, E.; Cao, Y.; Makris, C.; Li Z.-W.; Karin, M.; Ware, C.F.; Green, D.R. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity, 2002, 17(4), 525-535.
7. Ryseck, R.P.; Bull, P.; Takamiya, M.; Bours, V.; Siebenlist, U.; Dobrzanski, P.; Bravo, R. Relb, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol, 1992, 12(2), 674-684.
8. Sha, W.C.; Liou, H.C.; Tuomanen, E.I.; Baltimore, D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell, 1995, 80(2), 321-330.
9. Caamaño, J.H.; Rizzo, C.A.; Durham, S.K.; Barton, D.S.; Raventós-Suárez, C.; Snapper, C.M.; Bravo, R. Nuclear factor (NF)- kappa B2 (p100/p52) is required for normal splenic microarchitecture and b cell-mediated immune responses. J. Exp. Med., 1998, 187(2), 185-196. (Pubitemid 28060434)
10. Franzoso, G.; Carlson, L.; Poljak, L.; Shores, E. W.; Epstein, S.; Leonardi, A.; Grinberg, A.; Tran, T.; Scharton-Kersten, T.; Anver, M.; Love, P.; Brown, K.; Siebenlist, U. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J. Exp. Med., 1998, 187(2), 147-159. (Pubitemid 28060431)
11. Paxian, S.; Merkle, H.; Riemann, M.; Wilda, M.; Adler, G.; Hameister, H.; Liptay, S.; Pfeffer, K.; Schmid, R.M. Abnormal organogenesis of peyer's patches in mice deficient for NF-kappaB1, NF-kappaB2, and bcl-3. Gastroenterology, 2002, 122(7), 1853-1868.
12. Köntgen, F.; Grumont, R.J.; Strasser, A.; Metcalf, D.; Li, R.; Tarlinton, D.; Gerondakis, S. Mice lacking the c-Rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev, 1995, 9(16), 1965-1977.
13. Burkly, L.; Hession, C.; Ogata, L.; Reilly, C.; Marconi, L.A.; Olson, D.; Tizard, R.; Cate, R.; Lo, D. Expression of relb is required for the development of thymic medulla and dendritic cells. Nature, 1995, 373(6514), 531-536.
14. Weih, F.; Carrasco, D.; Durham, S. K.; Barton, D.S.; Rizzo, C.A.; Ryseck, R.P.; Lira, S. A.; Bravo, R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell, 1995, 80(2), 331-340.
15. Beg, A.A.; Sha, W.C.; Bronson, R.T.; Baltimore, D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in IkappaB alpha-deficient mice. Genes Dev., 1995, 9(22), 2736-2746.
16. Wang, Q.; Wang, X.; Evers, B.M. Induction of CIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J. Biol. Chem., 2003, 278(51), 51091-51099.
17. Baud, V.; Karin, M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov., 2009, 8(1), 33-40.
18. Lin, Y.; Bai, L.; Chen, W.; Xu, S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets, 2010, 14(1), 45-55.
19. Schütze, S.; Machleidt, T.; Krönke, M. The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J. Leukoc. Biol., 1994, 56(5), 533-541. (Pubitemid 24348808)
20. Tran-Thi, T.A.; Decker, K.; Baeuerle, P.A. Differential activation of transcription factors NF-kappa B and AP-1 in rat liver macrophages. Hepatology, 1995, 22(2), 613-619.
21. Sun, L.; Carpenter, G. Epidermal growth factor activation of NF-kappaB is mediated through IkappaBalpha degradation and intracellular free calcium. Oncogene, 1998, 16(16), 2095-2102. (Pubitemid 28211684)
22. Hoshi, S.; Goto, M.; Koyama, N.; Nomoto, K.; Tanaka, H. Regulation of vascular smooth muscle cell proliferation by nuclear factorkappaB and its inhibitor, I-kappaB. J. Biol. Chem., 2000, 275(2), 883-889. (Pubitemid 30051130)
23. Heck, S.; Lezoualc'h, F.; Engert, S.; Behl, C. Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB. J. Biol. Chem., 1999, 274(14), 9828-9835. (Pubitemid 129517962)
24. Olashaw, N.E.; Kowalik, T.F.; Huang, E.S.; Pledger, W.J. Induction of NF-kappa B-like activity by platelet-derived growth factor in mouse fibroblasts. Mol. Biol. Cell, 1992, 3(10), 1131-1139.
25. Di Donato, J.A.; Hayakawa, M.; Rothwarf, D.M.; Zandi, E.; Karin, M. A cytokine-responsive IkappaB kinase that activates the transcription factor nf-kappab. Nature, 1997, 388(6642), 548-554. (Pubitemid 27339997)
26. Mercurio, F.; Zhu, H.; Murray, B.W.; Shevchenko, A.; Bennett, B.L.; Li,J.; Young, D.B.; Barbosa, M.; Mann, M.; Manning, A.; Rao, A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science, 1997, 278(5339), 860-866.
27. Zandi, E.; Chen, Y.; Karin, M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science, 1998, 281(5381), 1360-1363. (Pubitemid 28406830)
28. Zandi, E.; Rothwarf, D.M.; Delhase, M.; Hayakawa, M.; Karin, M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell, 1997, 91(2), 243-252. (Pubitemid 27456391)
29. Rothwarf, D.M.; Karin, M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci. STKE, 1999(5), RE1
30. Karin, M. NF-kappaB and cancer: mechanisms and targets. Mol. Carcinog., 2006, 45(6), 355-361.
31. Yamaoka, S.; Courtois, G.; Bessia, C.; Whiteside, S. T.; Weil, R.; Agou, F.; Kirk, H.E.; Kay, R.J.; Israël, A. Complementation cloning of NEMO, a component of the ikappa b kinase complex essential for NF-kappa B activation. Cell, 1998, 93(7), 1231-1240. (Pubitemid 28307427)
32. Delhase, M.; Karin, M. The I kappa B kinase: a master regulator of NF-kappa B, innate immunity, and epidermal differentiation. Cold Spring Harb. Symp. Quant. Biol., 1999, 64, 491-503. (Pubitemid 30329315)
33. Johnson, L.N.; Noble, M.E.; Owen, D.J. Active and inactive protein kinases: structural basis for regulation. Cell, 1996, 85(2), 149-158. (Pubitemid 26118158)
34. Ben-Yair, R.; Kalcheim, C. Lineage analysis of the avian dermomyotome sheet reveals the existence of single cells with both dermal and muscle progenitor fates. Development, 2005, 132(4), 689-701. (Pubitemid 40352829)
35. Yaron, A.; Gonen, H.; Alkalay, I.; Hatzubai, A.; Jung, S.; Beyth, S.; Mercurio, F.; Manning, A.M.; Ciechanover, A.; Ben-Neriah, Y. Inhibition of NF-kappa-B cellular function via specific targeting of the i-kappa-b-ubiquitin ligase. EMBO J., 1997, 16(21), 6486-6494. (Pubitemid 27483274)
36. Fuchs, S.Y.; Chen, A.; Xiong, Y.; Pan, Z.Q.; Ronai, Z. HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Oncogene, 1999, 18(12), 2039-2046.
37. Alkalay, I.; Yaron, A.; Hatzubai, A.; Orian, A.; Ciechanover, A.; Ben-Neriah, Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A., 1995, 92(23), 10599-10603. (Pubitemid 3009135)
38. Bonizzi, G.; Bebien, M.; Otero, D.C.; Johnson-Vroom, K.E.; Cao, Y.; Vu, D.; Jegga, A.G.; Aronow, B.J.; Ghosh, G.; Rickert, R.C.; Karin, M. Activation of IKKalpha target genes depends on recognition of specific kappa B binding sites by RelB:p52 dimers. EMBO J., 2004, 23(21), 4202-4210. (Pubitemid 39546158)
39. Leung, T.H.; Hoffmann, A.; Baltimore, D. One nucleotide in a kappa B site can determine cofactor specificity for NF-kappa B dimers. Cell, 2004, 118(4), 453-464. (Pubitemid 39485665)
40. Senftleben, U.; Cao, Y.; Xiao, G.; Greten, F.R.; Krähn, G.; Bonizzi, G.; Chen, Y.; Hu, Y.; Fong, A.; Sun, S.C.; Karin, M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 2001, 293(5534), 1495-1499. (Pubitemid 32801552)
41. Matsushima, A.; Kaisho, T.; Rennert, P.D.; Nakano, H.; Kurosawa, K.; Uchida, D.; Takeda, K.; Akira, S.; Matsumoto, M. Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor 1. J. Exp. Med., 2001, 193(5), 631-636. (Pubitemid 32539559)
42. Pomerantz, J.L.; Baltimore, D. Two pathways to NF-kappaB. Mol Cell, 2002,10(4), 693-695.
43. Hauer, J.; Püschner, S.; Ramakrishnan, P.; Simon, U.; Bongers, M.; Federle, C.; Engelmann, H. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc. Natl. Acad. Sci. U.S.A., 2005, 102(8), 2874-2879. (Pubitemid 40299884)
44. Jiang, X.; Takahashi, N.; Ando, K.; Otsuka, T.; Tetsuka, T.; Okamoto, T. NF-kappa B p65 transactivation domain is involved in the NF-kappa B-inducing kinase pathway. Biochem. Biophys. Res. Commun., 2003, 301(2), 583-590. (Pubitemid 36279281)
45. Brantley, D.M.; Chen, C.L.; Muraoka, R.S.; Bushdid, P.B.; Bradberry, J.L.; Kittrell, F.; Medina, D.; Matrisian, L.M.; Kerr, L.D.; Yull, F.E. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell, 2001, 12(5), 1445-1455.
46. Hinz, M.; Krappmann, D.; Eichten, A.; Heder, A.; Scheidereit, C.; Strauss, M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol., 1999, 19(4), 2690-2698. (Pubitemid 29144513)
47. Clément, J.F.; Meloche, S.; Servant, M.J. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res., 2008, 18(9), 889-899.
48. Salminen, A.; Huuskonen, J.; Ojala, J.; Kauppinen, A.; Kaarniranta, K.; Suuronen, T. Activation of innate immunity system during aging: NF-kappaB signaling is the molecular culprit of inflamm-aging. Ageing Res. Rev., 2008, 7(2), 83-105. (Pubitemid 351418294)
49. Ahmad, A.; Banerjee, S.; Wang, Z.; Kong, D.; Majumdar, A.P.; Sarkar, F.H. Aging and inflammation: etiological culprits of cancer. Curr. Aging Sci., 2009, 2(3), 174-186.
50. Salminen, A.; Kaarniranta, K. Insulin/iGF-1 paradox of aging: regulation via Akt/IKK/NF-kappaB signaling. Cell Signal., 2010, 22(4), 573-577.
51. Dahlman, J.M.; Wang, J.; Bakkar, N.; Guttridge, D.C. The rela/p65 subunit of NF-kappaB specifically regulates cyclin d1 protein stability: implications for cell cycle withdrawal and skeletal myogenesis. J. Cell Biochem., 2009, 106(1), 42-51.
52. Tozawa, K.; Sakurada, S.; Kohri, K.; Okamoto, T. Effects of anti-nuclear factor kappa B reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res., 1995, 55(18), 4162-4167.
53. Arun, P.; Brown, M.S.; Ehsanian, R.; Chen, Z.; Van Waes, C. Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase a contributes to the malignant phenotype of head and neck cancer. Clin. Cancer Res., 2009, 15(19), 5974-5984.
54. Lau, S.T.; Lin, Z.X.; Leung, P.S. Role of reactive oxygen species in brucein d-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. Br. J. Cancer, 2010, 102(3), 583-593.
55. Okamoto, T.; Sanda, T.; Asamitsu, K. NF-kappa B signaling and carcinogenesis. Curr. Pharm. Des., 2007, 13(5), 447-462.
56. Baldwin, A.S.; Azizkhan, J.C.; Jensen, D.E.; Beg, A.A.; Coodly, L.R. Induction of NF-kappa B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts. Mol. Cell. Biol., 1991, 11(10), 4943-4951.
57. Cheng, M.; Olivier, P.; Diehl, J.A.; Fero, M.; Roussel, M.F.; Roberts, J.M.; Sherr, C.J. The p21(cip1) and p27(kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J., 1999, 18(6), 1571-1583.
58. Guttridge, D.C.; Albanese, C.; Reuther, J.Y.; Pestell, R.G.; Baldwin, A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin d1. Mol. Cell Biol., 1999, 19(8), 5785-5799.
59. Albanese, C.; Johnson, J.; Watanabe, G.; Eklund, N.; Vu, D.; Arnold, A.; Pestell, R.G. Transforming p21ras mutants and c-ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem., 1995, 270(40), 23589-23597.
60. Watanabe, G.; Albanese, C.; Lee, R.J.; Reutens, A.; Vairo, G.; Henglein, B.; Pestell, R.G. Inhibition of cyclin D1 kinase activity is associated with e2f-mediated inhibition of cyclin D1 promoter activity through e2f and Sp1. Mol. Cell. Bio.l, 1998, 18(6), 3212-3222.
61. Lee, R.J.; Albanese, C.; Fu, M.; D'Amico, M.; Lin, B., Watanabe, G.; Haines, G.K.; Siegel, P.M.; Hung, M.C.; Yarden, Y.; Horowitz, J.M.; Muller, W.J.; Pestell, R.G. Cyclin D1 is required for transformation by activated neu and is induced through an e2f-dependent signaling pathway. Mol. Cell. Biol., 2000, 20(2), 672-683. (Pubitemid 30023109)
62. Bromberg, J.F.; Horvath, C.M.; Besser, D.; Lathem, W.W.; Darnell, J.E. Stat3 activation is required for cellular transformation by v-Src. Mol. Cell. Biol., 1998, 18(5), 2553-2558. (Pubitemid 28183425)
63. Matsumura, I.; Kitamura, T.; Wakao, H.; Tanaka, H.; Hashimoto, K.; Albanese, C.; Downward, J.; Pestell, R.G.; Kanakura, Y. Transcriptional regulation of the cyclin d1 promoter by stat5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J., 1999, 18(5), 1367-1377. (Pubitemid 29110320)
64. Joyce, D.; Albanese, C.; Steer, J.; Fu, M.; Bouzahzah, B.; & Pestell, R.G. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev, 2001, 12(1), 73-90.
65. Penzo, M.; Massa, P.E.; Olivotto, E.; Bianchi, F.; Borzi, R.M.; Hanidu, A.; Li, X.; Li, J.; Marcu, K.B. Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by e2f or foxm1. J. Cell Physiol., 2009, 218(1), 215-227.
66. Araki, K.; Kawauchi, K.; Tanaka, N. IKK/NF-kappaB signaling pathway inhibits cell-cycle progression by a novel Rb-independent suppression system for e2f transcription factors. Oncogene, 2008, 27(43), 5696-5705.
67. Vaupel, J.W.; Carey, J.R.; Christensen, K.; Johnson, T.E.; Yashin, A.I.; Holm, N.V.; Iachine, I.A.; Kannisto, V.; Khazaeli, A.A.; Liedo, P.; Longo, V.D.; Zeng, Y.; Manton, K.G.; Curtsinger, J.W. Biodemographic trajectories of longevity. Science, 1998, 280(5365), 855-860.
68. Lin, S.J.; Kaeberlein, M.; Andalis, A.A.; Sturtz, L.A.; Defossez, P.A.; Culotta, V.C.; Fink, G.R.; Guarente, L. Calorie restriction extends saccharomyces cerevisiae lifespan by increasing respiration. Nature, 2002, 418(6895), 344-348. (Pubitemid 34790687)
69. Rogina, B.; Helfand, S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(45), 15998-16003.
70. Kirkwood, T.B.; Boys, R.J.; Gillespie, C.S.; Proctor, C.J.; Shanley, D.P.; Wilkinson, D.J. Towards an e-biology of ageing: integrating theory and data. Nat. Rev. Mo.l Cell. Biol., 2003, 4(3), 243-249.
71. Campisi, J.; d'Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell. Biol., 2007, 8(9), 729-740.
72. Macieira-Coelho, A. Implications of the reorganization of the cell genome for aging or immortalization of dividing cells in vitro. Gerontology, 1980, 26(5), 276-282. (Pubitemid 10110029)
73. Wilson, V.L.; Jones, P.A. DNA methylation decreases in aging but not in immortal cells. Science, 1983, 220(4601), 1055-1057.
74. Calvanese, V.; Lara, E.; Kahn, A.; Fraga, M.F. The role of epigenetics in aging and age-related diseases. Ageing Res. Rev., 2009, 8(4), 268-276.
75. Sinclair, D.A.; Oberdoerffer, P. The ageing epigenome: damaged beyond repair? Ageing Res. Rev., 2009, 8(3), 189-198.
76. Vertino, P.M.; Issa, J.P.; Pereira-Smith, O.M.; Baylin, S.B. Stabilization of DNA methyltransferase levels and CPG island hypermethylation precede SV40-induced immortalization of human fibroblasts. Cell Growth Differ., 1994, 5(12), 1395-1402.
77. Young, J.I.; Smith, J.R. DNA methyltransferase inhibition in normal human fibroblasts induces a p21-dependent cell cycle withdrawal. J. Biol. Chem., 2001, 276(22), 19610-19616. (Pubitemid 37411301)
78. Bjornsson, H.T.; Sigurdsson, M.I.; Fallin, M.D.; Irizarry, R.A.; Aspelund, T.M.; Cui, H.; Yu, W.; Rongione, M.A.; Ekström, T.J.; Harris, T.B.; Launer, L.J.; Eiriksdottir, G.; Leppert, M.F.; Sapienza, C.; Gudnason, V.; Feinberg, A.P. Intra-individual change over time in DNA methylation with familial clustering. JAMA, 2008, 299(24), 2877-2883. (Pubitemid 351930887)
79. Chan, H.M.; La Thangue, N.B. p300/CBP proteins: Hats for transcriptional bridges and scaffolds. J. Cell Sci., 2001, 114(Pt 13), 2363-2373.
80. Yao, T.P.; Oh, S.P.; Fuchs, M.; Zhou, N.D.; Ch'ng, L.E.; Newsome, D., Bronson, R.T.; Li, E.; Livingston, D.M.; Eckner, R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell, 1998, 93(3), 361-372.
81. Bandyopadhyay, D.; Okan, N.A.; Bales, E.; Nascimento, L.; Cole, P.A.; Medrano, E.E. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res. 2002, , 6231-6239.
82. Heilbronn, L.K.; Ravussin, E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am .J. Clin. Nutr., 2003, 78(3), 361-369. (Pubitemid 39663500)
83. Burzynski, S.R. Gene silencing-a new theory of aging. Med. Hypotheses, 2003, 60(4), 578-583.
84. Tatar, M.; Bartke, A.; Antebi, A. The endocrine regulation of aging by insulin-like signals. Science, 2003, 299(5611), 1346-1351. (Pubitemid 36254639)
85. Brewer, G.J. Epigenetic oxidative redox shift (EORS) theory of aging unifies the free radical and insulin signaling theories. Exp. Gerontol., 2010, 45(3), 173-179.
86. Gems, D.; Partridge, L. Insulin/IGF signalling and ageing: seeing the bigger picture. Curr. Opin. Genet. Dev, 2001, 11(3), 287-292. (Pubitemid 32480295)
87. Finch, C.E.; Ruvkun, G. The genetics of aging. Annu. Rev. Genomics Hum. Genet., 2001, 2, 435-462.
88. Selman, C.; Lingard, S.; Choudhury, A.I.; Batterham, R.L.; Claret, M.; Clements, M.; Ramadani, F.; Okkenhaug, K.; Schuster, E.; Blanc, E.; Piper, M.D.; Al-Qassab, H.; Speakman, J.R.; Carmignac, D.; Robinson, I.C.; Thornton, J.M.; Gems, D.; Partridge, L.; Withers, D.J. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J., 2008, 22(3), 807-818.
89. Blackburn, E.H. Switching and signaling at the telomere. Cell, 2001, 106(6), 661-673.
90. Shay, J.W.; Wright, W.E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis, 2005, 26(5), 867-874.
91. Lavu, S.; Boss, O.; Elliott, P.J.; Lambert, P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov., 2008, 7(10), 841-853.
92. Blander, G.; Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem., 2004, 73, 417-435.
93. Harting, K.; Knöll, B. Sirt2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology. Eur. J. Cell. Biol., 2010, 89(2-3), 262-269.
94. Rodgers, J.; Lerin, C.; Haas, W.; Gygi, S.; Spiegelman, B.; Puigserver, P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and Sirt1. Nature, 2005, 434(7029), 113-118. (Pubitemid 40349395)
95. Freyssenet, D. Energy sensing and regulation of gene expression in skeletal muscle. J. Appl. Physiol., 2007, 102(2), 529-540. (Pubitemid 46220880)
96. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the Sirt1 deacetylase. EMBO J., 2004, 23(12), 2369-2380. (Pubitemid 38954844)
97. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of human sirt1 activation by resveratrol. J. Biol. Chem., 2005, 280(17), 17187-17195.
98. Nayagam, V.M.; Wang, X.; Tan, Y.C.; Poulsen, A.; Goh, K.C.; Ng, T.; Wang, H.; Song, H.Y.; Ni, B.; Entzeroth, M.; Stünkel, W. Sirt1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen, 2006, 11(8), 959-967. (Pubitemid 44847150)
99. Yang, Y.; Fu, W.; Chen, J.; Olashaw, N.; Zhang, X.; Nicosia, S.; Bhalla, K.; Bai, W. Sirt1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat. Cell. Biol., 2007, 9(11), 1253-1262. (Pubitemid 350042357)
100. Kawahara, T.L.; Michishita, E.; Adler, A.S.; Damian, M.; Berber, E.; Lin, M.; McCord, R.A.; Ongaigui, K.C.; Boxer, L.D.; Chang, H.Y.; Chua, K.F. Sirt6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell, 2009, 136(1), 62-74.
101. Lombard, D.B.; Schwer, B.; Alt, F.W.; Mostoslavsky, R. Sirt6 in DNA repair, metabolism and ageing. J. Intern. Med., 2008, 263(2), 128-141.
102. Liszt, G.; Ford, E.; Kurtev, M.; Guarente, L. Mouse Sir2 homolog Sirt6 is a nuclear ADP-ribosyltransferase. J. Biol. Chem., 2005, 280(22), 21313-21320. (Pubitemid 40805693)
103. Staal, F.J.; Roederer, M.; Herzenberg, L.A.; Herzenberg, L.A. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A., 1990, 87(24), 9943-9947.
104. Okamoto, T.; Ogiwara, H.; Hayashi, T.; Mitsui, A.; Kawabe, T.; Yodoi, J. Human thioredoxin/adult T cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism. Int. Immunol., 1992, 4(7), 811-819.
105. Hayashi, T.; Ueno, Y.; Okamoto, T. Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem., 1993, 268(15), 11380-11388. (Pubitemid 23162336)
106. Gosselin, K.; Abbadie, C. Involvement of Rel/NF-kappa B transcription factors in senescence. Exp. Gerontol., 2003, 38(11-12), 1271-1283. (Pubitemid 38041214)
107. Zdanov, S.; Bernard, D.; Debacq-Chainiaux, F.; Martien, S.; Gosselin, K.; Vercamer, C.; Chelli, F.; Toussaint, O.; Abbadie, C. Normal or stress-induced fibroblast senescence involves COX-2 activity. Exp. Cell Res., 2007, 313(14), 3046-3056. (Pubitemid 47125881)
108. Aspinall, R.; Andrew, D. Immunosenescence: potential causes and strategies for reversal. Biochem. Soc. Trans., 2000, 28(2), 250-254.
109. Kovaiou, R.D.; Grubeck-Loebenstein, B. Age-associated changes within CD4+ T cells. Immunol Lett, 2006, 107(1), 8-14. (Pubitemid 44332549)
110. Franceschi, C.; Valensin, S.; Bonafè, M.; Paolisso, G.; Yashin, A.I.; Monti, D.; De Benedictis, G. The network and the remodeling theories of aging: historical background and new perspectives. Exp. Gerontol., 2000, 35(6-7), 879-896.
111. Franceschi, C.; Bonafè, M.; Valensin, S.; Olivieri, F.M; De Luca, M.; Ottaviani, E.; De Benedictis, G. Inflamm-aging. an evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci., 2000, 908, 244-254.
112. Perkins, N. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Bio.l, 2007, 8(1), 49-62. (Pubitemid 46012014)
113. Okamoto, T. NF-kappaB and rheumatic diseases. Endocr. Metab. Immune Disord. Drug Targets, 2006, 6(4), 359-372.
114. Adler, A.S.; Sinha, S.; Kawahara, T.L.; Zhang, J.Y.; Segal, E.; Chang, H.Y.. Motif module MAP reveals enforcement of aging by continual NF-kappaB activity. Genes Dev., 2007, 21(24), 3244-3257.
115. Adler, A.S.; Kawahara, T.L.; Segal, E.; Chang, H.Y. Reversal of aging by NFkappaB blockade. Cell Cycle, 2008, 7(5), 556-559.
116. Xu, X.P.; Meisel, S.R.; Ong, J.M.; Kaul, S.; Cercek, B.; Rajavashisth, T.B.; Sharifi, B.; Shah, P.K. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation, 1999, 99(8), 993-998.
117. Kiningham, K.K.; Xu, Y.; Daosukho, C.; Popova, B.; St Clair, D.K. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. Biochem. J., 2001, 353(Pt 1), 147-156. (Pubitemid 32094609)
118. Song, Y.S.; Lee, Y.-S.; Narasimhan, P.; Chan, P.H. Reduced oxidative stress promotes NF-kappaB-mediated neuroprotective gene expression after transient focal cerebral ischemia: lymphocytotrophic cytokines and antiapoptotic factors. J. Cereb. Blood Flow Metab., 2007, 27(4), 764-775.
119. Song, Y.S.; Lee, Y.S.; Chan, P.H. Oxidative stress transiently decreases the IKK complex (IKKalpha, beta, and gamma), an upstream component of NF-kappaB signaling, after transient focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab., 2005, 25(10), 1301-1311.
120. Mattson, M.P.; Culmsee, C.; Yu, Z.; Camandola, S. Roles of nuclear factor kappaB in neuronal survival and plasticity. J. Neurochem., 2000, 74(2), 443-456. (Pubitemid 30053716)
121. Mollace, V.; Muscoli, C.; Masini, E.; Cuzzocrea, S.; Salvemini, D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev., 2005, 57(2), 217-252. (Pubitemid 41043885)
122. Graham, B.; Gibson, S.B. The two faces of NFkappaB in cell survival responses. Cell Cycle, 2005, 4(10), 1342-1345.
123. Kashatus, D.; Cogswell, P.; Baldwin, A.S. Expression of the bcl-3 proto-oncogene suppresses p53 activation. Genes Dev., 2006, 20(2), 225-235. (Pubitemid 43112940)
124. Rocha, S.; Perkins, N.D. Arf the integrator: linking NF-kappaB, p53 and checkpoint kinases. Cell Cycle, 2005, 4(6), 756-759.
125. Jeong, S.-J.; Pise-Masison, C.A.; Radonovich, M.F.; Park, H.U.; Brady, J.N. Activated Akt regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene, 2005, 24(44), 6719-6728.
126. Huang, J.; Gabrielsen, J.S.; Cooksey, R.C.; Luo, B.; Boros, L.G.; Jones, D.L.; Jouihan, H.A.; Soesanto, Y.; Knecht, L.; Hazel, M.W.; Kushner, J.P.; McClain, D.A. Increased glucose disposal and AMP-dependent kinase signaling in a mouse model of hemochromatosis. J. Biol. Chem., 2007, 282(52), 37501-37507.
127. Bohuslav, J.; Chen, L.F.; Kwon, H.; Mu, Y.; Greene, W.C. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem., 2004, 279(25), 26115-26125.
128. Gingras, A.C.; Raught, B.; Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev, 2001, 15(7), 807-826.
129. Sabatini, D.M.; Erdjument-Bromage, H.; Lui, M.; Tempst, P.; Snyder, S.H. Raft1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell, 1994, 78(1), 35-43.
130. Kim, S.M.; Lee, S.Y.; Yuk, D.Y.; Moon, D.C.; Choi, S.S.; Kim, Y.; Han, S.B.; Oh, K.W.; Hong, J.T. Inhibition of NF-kappaB by ginsenoside RG3 enhances the susceptibility of colon cancer cells to docetaxel. Arch. Pharm. Res., 2009, 32(5), 755-765.
131. Guertin, D.A.; Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12(1), 9-22.
132. Nicklin, P.; Bergman, P.; Zhang, B.; Triantafellow, E.; Wang, H.; Nyfeler, B.; Yang, H.; Hild, M.; Kung, C.; Wilson, C.; Myer, V.E.; MacKeigan, J.P.; Porter, J.A.; Wang, Y.K.; Cantley, L.C.; Finan, P.M.; Murphy, L.O. Bidirectional transport of amino acids regulates mtor and autophagy. Cell, 2009, 136(3), 521-534.
133. Young, A.R.; Narita, M.; Ferreira, M.; Kirschner, K.; Sadaie, M.; Darot, J.F.; Tavaré, S.; Arakawa, S.; Shimizu, S.; Watt, F.M.; Narita, M. Autophagy mediates the mitotic senescence transition. Genes Dev., 2009, 23(7), 798-803.
134. Lee, D.F.; Kuo, H.P.; Chen, C.T.; Hsu, J.M.; Chou, C.K.; Wei, Y.; Sun, H.L.; Li, L.Y.; Ping, B.; Huang, W.C.; He, X.; Hung, J.Y.; Lai, C.C.; Ding, Q.; Su, J.L.; Yang, J.Y.; Sahin, A.A.; Hortobagyi, G.N.; Tsai, F.J.; Tsai, C.H.; Hung, M.C. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell, 2007, 130(3), 440-455.
135. Budanov, A.V.; Karin, M. p53 target genes Sestrin1 and Sestrin2 connect genotoxic stress and mTOR signaling. Cell, 2008, 134(3), 451-460.
136. Levine, A.J.; Feng, Z.; Mak, T.W.; You, H.; Jin, S. Coordination and communication between the p53 and IGF-1-Akt-TOR signal transduction pathways. Genes Dev., 2006, 20(3), 267-275. (Pubitemid 43200281)
137. Budanov, A.V.; Shoshani, T.; Faerman, A.; Zelin, E.; Kamer, I.; Kalinski, H.; Gorodin, S.; Fishman, A.; Chajut, A.; Einat, P.; Skaliter, R.; Gudkov, A.V.; Chumakov, P.M.; Feinstein, E. Identification of a novel stress-responsive gene HI95 involved in regulation of cell viability. Oncogene, 2002, 21(39), 6017-6031.
138. Budanov, A.V.; Sablina, A.A.; Feinstein, E.; Koonin, E.V.; Chumakov, P.M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AHPD. Science, 2004, 304(5670), 596-600.
139. Matheu, A.; Maraver, A.; Klatt, P.; Flores, I.; Garcia-Cao, I.; Borras, C.; Flores, J.; Vina, J.; Blasco, M.; Serrano, M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature, 2007, 448(7151), 375-379. (Pubitemid 47080339)
140. Budanov, A.V.; Sablina, A.A.; Feinstein, E.; Koonin, E.V.; Chumakov, P.M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AHPD. Science, 2004, 304(5670), 596-600.
141. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T. ; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298(5600), 1912-1934. (Pubitemid 35425239)
142. Hardie, D.G.; Scott, J.W.; Pan, D.A.; Hudson, E. R. Management of cellular energy by the amp-activated protein kinase system. FEBS Lett., 2003, 546(1), 113-120.
143. Legembre, P.; Schickel, R.; Barnhart, B.C.; Peter, M.E. Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness. J. Biol. Chem., 2004, 279(45), 46742-46747.
144. Tsuchihara, K.; Ogura, T.; Fujioka, R.; Fujii, S.; Kuga, W.; Saito, M.; Ochiya, T.; Ochiai, A.; Esumi, H. Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci. Cancer Sci., 2008, 99(4), 677-682. (Pubitemid 351448070)